Charles Bennett to Antineoplastic Agents, Hormonal
This is a "connection" page, showing publications Charles Bennett has written about Antineoplastic Agents, Hormonal.
Connection Strength
1.477
-
Racial differences in receipt of adjuvant hormonal therapy among Medicaid enrollees in South Carolina diagnosed with breast cancer. Breast Cancer Res Treat. 2016 05; 157(1):193-200.
Score: 0.488
-
Editorial comment. Urology. 2013 Jan; 81(1):154; author reply 154.
Score: 0.388
-
Cost-effective models for flutamide for prostate carcinoma patients: are they helpful to policy makers? Cancer. 1996 May 01; 77(9):1854-61.
Score: 0.122
-
The utility of prostate-specific antigen in the management of advanced prostate cancer. BJU Int. 2013 Sep; 112(5):548-60.
Score: 0.100
-
Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol. 2007 Apr 20; 25(12):1596-605.
Score: 0.065
-
American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. J Clin Oncol. 2004 Jul 15; 22(14):2927-41.
Score: 0.054
-
Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. Cancer. 2002 Jul 15; 95(2):361-76.
Score: 0.047
-
Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med. 2000 Apr 04; 132(7):566-77.
Score: 0.040
-
Maximal androgen blockade for advanced prostate cancer. Cochrane Database Syst Rev. 2000; (2):CD001526.
Score: 0.039
-
Comparative study of the clinical efficacy of two dosing regimens of flutamide. Mol Urol. 2000; 4(3):259-63;discussion 265.
Score: 0.039
-
Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer. Evid Rep Technol Assess (Summ). 1999 May; (4):i-x, 1-246, I1-36, passim.
Score: 0.038
-
Treatment considerations for persons with metastatic prostate cancer: survival versus out-of-pocket costs. Urology. 1997 Feb; 49(2):218-24.
Score: 0.032
-
Reduced penile size and treatment regret in men with recurrent prostate cancer after surgery, radiotherapy plus androgen deprivation, or radiotherapy alone. Urology. 2013 Jan; 81(1):130-4.
Score: 0.024